Literature DB >> 36163566

Robotic approach mitigates the effect of major complications on survival after pancreaticoduodenectomy for periampullary cancer.

Thiagarajan Meyyappan1, Greg C Wilson2, Herbert J Zeh3, Melissa E Hogg4, Kenneth K Lee1, Amer H Zureikat1, Alessandro Paniccia5.   

Abstract

BACKGROUND: Major complications (MCs) after pancreaticoduodenectomy (PD) are a known independent predictor of worse oncologic outcomes. There are limited data on the effect of major complications on long-term outcomes after robotic PD (RPD). The aim of this study is to compare the effect of MC on overall (OS) and disease-free survival (DFS) after RPD and open PD (OPD).
METHODS: This is a single-center, retrospective review of a prospectively maintained database of all patients undergoing PD for periampullary cancer including ampullary adenocarcinoma, distal cholangiocarcinoma, and duodenal carcinoma. Univariate analysis was performed on all clinical, pathologic, and treatment factors. MCs were defined as Clavien-Dindo ≥ grade 3. Kaplan-Maier survival analysis was performed with log-rank test for group comparison. Multivariable Cox regression analysis was used to identify factors associated with overall survival (OS) in both the OPD and RPD groups.
RESULTS: A total of 190 patients with ampullary carcinoma (n = 98), cholangiocarcinoma (n = 55), and duodenal adenocarcinoma (n = 37) were examined over the study period with 61.1% (n = 116) undergoing RPD and 38.9% (n = 74) undergoing OPD. There was no significant difference in patient demographics between the RPD and OPD cohorts. Furthermore, R0 resection rates, tumor size, and lymph node involvement were similar between the RPD and OPD cohorts. OPD had higher rate of MC (40.5% vs 28.3% in RPD, p = 0.011) including clinically relevant pancreatic fistula (25.7% vs 8.6%, p = 0.001) and wound infection (34.5% vs 13.8%, p < 0.001). MCs were associated with a lower OS in the OPD cohort (HR = 2.18, 95%CI 1.0-4.55, p = 0.038). MCs were not associated with OS in the RPD cohort (HR = 1.55, 95%CI 0.87-2.76, p = 0.14).
CONCLUSION: MCs are associated with worse patient outcomes after OPD but not after RPD. Robotic approach mitigates and possibly abrogates the negative effects of MCs on patient outcomes after PD for malignancy and is associated with improved adjuvant chemotherapy completion rates.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Pancreaticoduodenectomy; Periampullary cancer; Robotics; Whipple

Year:  2022        PMID: 36163566     DOI: 10.1007/s00464-022-09638-4

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  14 in total

1.  Outcomes after robot-assisted pancreaticoduodenectomy for periampullary lesions.

Authors:  Herbert J Zeh; Amer H Zureikat; Aaron Secrest; Mustapha Dauoudi; David Bartlett; A James Moser
Journal:  Ann Surg Oncol       Date:  2011-09-24       Impact factor: 5.344

2.  Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial.

Authors:  Min Wang; Dewei Li; Rufu Chen; Xiaobing Huang; Jing Li; Yahui Liu; Jianhua Liu; Wei Cheng; Xuemin Chen; Wenxing Zhao; Jingdong Li; Zhijian Tan; Heguang Huang; Deyu Li; Feng Zhu; Tingting Qin; Jingdong Ma; Guangsheng Yu; Baoyong Zhou; Shangyou Zheng; Yichen Tang; Wei Han; Lingyu Meng; Jianji Ke; Feng Feng; Botao Chen; Xinmin Yin; Weibo Chen; Hongqin Ma; Jian Xu; Yifeng Liu; Ronggui Lin; Yadong Dong; Yahong Yu; Jun Liu; Hang Zhang; Renyi Qin
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-04-27

3.  Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer.

Authors:  Anh-Thu Le; Bin Huang; Dima Hnoosh; Hayder Saeed; Sean P Dineen; Peter J Hosein; Eric B Durbin; Mahesh Kudrimoti; Patrick C McGrath; Ching-Wei D Tzeng
Journal:  J Surg Res       Date:  2017-03-18       Impact factor: 2.192

4.  Long-term oncologic outcomes of robotic and open pancreatectomy in a national cohort of pancreatic adenocarcinoma.

Authors:  Ibrahim Nassour; Sharon B Winters; Richard Hoehn; Samer Tohme; Mohamed A Adam; David L Bartlett; Kenneth K Lee; Alessandro Paniccia; Amer H Zureikat
Journal:  J Surg Oncol       Date:  2020-04-29       Impact factor: 3.454

5.  Safety and oncologic efficacy of robotic compared to open pancreaticoduodenectomy after neoadjuvant chemotherapy for pancreatic cancer.

Authors:  Ibrahim Nassour; Samer Tohme; Richard Hoehn; Mohamed Abdelgadir Adam; Amer H Zureikat; Paniccia Alessandro
Journal:  Surg Endosc       Date:  2020-05-21       Impact factor: 4.584

6.  Morbidity and mortality of pancreaticoduodenectomy for benign and premalignant pancreatic neoplasms.

Authors:  Timothy E Newhook; Damien J LaPar; James M Lindberg; Todd W Bauer; Reid B Adams; Victor M Zaydfudim
Journal:  J Gastrointest Surg       Date:  2015-03-24       Impact factor: 3.452

7.  Robotic pancreaticoduodenectomy: comparison of complications and cost to the open approach.

Authors:  E H Baker; S W Ross; R Seshadri; R Z Swan; D A Iannitti; D Vrochides; J B Martinie
Journal:  Int J Med Robot       Date:  2015-07-23       Impact factor: 2.547

8.  Robotic Pancreaticoduodenectomy Is Associated with Decreased Clinically Relevant Pancreatic Fistulas: a Propensity-Matched Analysis.

Authors:  Jianpeng Cai; Rajesh Ramanathan; Mazen S Zenati; Amr Al Abbas; Melissa E Hogg; Herbert J Zeh; Amer H Zureikat
Journal:  J Gastrointest Surg       Date:  2019-07-02       Impact factor: 3.452

9.  Mortality after pancreaticoduodenectomy: assessing early and late causes of patient death.

Authors:  Sowmya Narayanan; Allison N Martin; Florence E Turrentine; Todd W Bauer; Reid B Adams; Victor M Zaydfudim
Journal:  J Surg Res       Date:  2018-06-27       Impact factor: 2.192

10.  Pancreatic Tissue-Derived Extracellular Matrix Bioink for Printing 3D Cell-Laden Pancreatic Tissue Constructs.

Authors:  Jaewook Kim; Myungji Kim; Dong Gyu Hwang; In Kyong Shim; Song Cheol Kim; Jinah Jang
Journal:  J Vis Exp       Date:  2019-12-13       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.